1103 related articles for article (PubMed ID: 28331080)
21. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
22. Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.
Schmeisser F; Vasudevan A; Verma S; Wang W; Alvarado E; Weiss C; Atukorale V; Meseda C; Weir JP
PLoS One; 2015; 10(1):e0117108. PubMed ID: 25629172
[TBL] [Abstract][Full Text] [Related]
23. Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes.
Lee AC; Zhu H; Zhang AJ; Li C; Wang P; Li C; Chen H; Hung IF; To KK; Yuen KY
Clin Vaccine Immunol; 2015 Dec; 22(12):1235-43. PubMed ID: 26446420
[TBL] [Abstract][Full Text] [Related]
24. H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus.
Rudenko L; Isakova-Sivak I; Donina S
Vaccine; 2013 Oct; 31(42):4702-5. PubMed ID: 23988294
[TBL] [Abstract][Full Text] [Related]
25. A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
Yang JR; Chen CY; Kuo CY; Cheng CY; Lee MS; Cheng MC; Yang YC; Wu CY; Wu HS; Liu MT; Hsiao PW
Antiviral Res; 2016 Feb; 126():8-17. PubMed ID: 26593980
[TBL] [Abstract][Full Text] [Related]
26. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
[TBL] [Abstract][Full Text] [Related]
27. Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine.
Carter DM; Bloom CE; Kirchenbaum GA; Tsvetnitsky V; Isakova-Sivak I; Rudenko L; Ross TM
Vaccine; 2015 Jan; 33(1):108-16. PubMed ID: 25448100
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a parainfluenza virus 5 (PIV5)-based H7N9 vaccine in mice and guinea pigs: antibody titer towards HA was not a good indicator for protection.
Li Z; Gabbard JD; Johnson S; Dlugolenski D; Phan S; Tompkins SM; He B
PLoS One; 2015; 10(3):e0120355. PubMed ID: 25803697
[TBL] [Abstract][Full Text] [Related]
29. Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice.
Chang H; Duan J; Zhou P; Su L; Zheng D; Zhang F; Fang F; Li X; Chen Z
Microbes Infect; 2017 Dec; 19(12):616-625. PubMed ID: 28899814
[TBL] [Abstract][Full Text] [Related]
30. Development of an Inactivated H7N9 Subtype Avian Influenza Serological DIVA Vaccine Using the Chimeric HA Epitope Approach.
Sun Z; Wang Q; Li G; Li J; Chen S; Qin T; Ma H; Peng D; Liu X
Microbiol Spectr; 2021 Oct; 9(2):e0068721. PubMed ID: 34585985
[TBL] [Abstract][Full Text] [Related]
31. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
Front Immunol; 2018; 9():2312. PubMed ID: 30356772
[TBL] [Abstract][Full Text] [Related]
32. Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.
Tan GS; Leon PE; Albrecht RA; Margine I; Hirsh A; Bahl J; Krammer F
PLoS Pathog; 2016 Apr; 12(4):e1005578. PubMed ID: 27081859
[TBL] [Abstract][Full Text] [Related]
33. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.
Klausberger M; Wilde M; Palmberger D; Hai R; Albrecht RA; Margine I; Hirsh A; García-Sastre A; Grabherr R; Krammer F
Vaccine; 2014 Jan; 32(3):355-62. PubMed ID: 24262313
[TBL] [Abstract][Full Text] [Related]
34. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
Ni Y; Guo J; Turner D; Tizard I
Front Immunol; 2018; 9():1815. PubMed ID: 30140267
[TBL] [Abstract][Full Text] [Related]
35. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
[TBL] [Abstract][Full Text] [Related]
36. Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.
Prabakaran M; Kumar SR; Raj KV; Wu X; He F; Zhou J; Kwang J
Antiviral Res; 2014 Sep; 109():149-59. PubMed ID: 24997413
[TBL] [Abstract][Full Text] [Related]
37. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.
Zhang L; Jia N; Li J; Han Y; Cao W; Wang S; Huang Z; Lu S
Hum Vaccin Immunother; 2014; 10(7):1949-58. PubMed ID: 25424804
[TBL] [Abstract][Full Text] [Related]
38. Cross-reactivity between avian influenza A (H7N9) virus and divergent H7 subtypic- and heterosubtypic influenza A viruses.
Guo L; Wang D; Zhou H; Wu C; Gao X; Xiao Y; Ren L; Paranhos-Baccalà G; Shu Y; Jin Q; Wang J
Sci Rep; 2016 Feb; 6():22045. PubMed ID: 26907865
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of avian influenza virus isolated from ducks as a potential live vaccine candidate against novel H7N9 viruses.
Jiang WM; Wang SC; Liu HL; Yu JM; Du X; Hou GY; Li JP; Liu S; Wang KC; Zhuang QY; Liu XM; Chen JM
Vaccine; 2014 Nov; 32(48):6433-9. PubMed ID: 25285880
[TBL] [Abstract][Full Text] [Related]
40. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
